Ambrobene, tablets 30 mg 20 pcs

Pharmacotherapeutic group: prescribing mucolytic agent.

ATX code: R05CB06

Pharmacological action

Pharmacodynamics:

Ambroxol is a benzylamine, a metabolite of bromhexine. It differs from bromhexin in the absence of a methyl group and the presence of a hydroxyl group in the para-trans position of the cyclohexyl ring. It has secretomotor, secretolytic and expectorant action.

After oral administration the action comes within 30 minutes and lasts for 6-12 hours (depending on the dose taken).

Doclinical studies have shown that ambroxol stimulates serous cells of the bronchial mucous membrane glands. By activating ciliated epithelial cells and reducing sputum viscosity, it improves mucociliary transport.

Ambroxol activates surfactant formation with a direct effect on alveolar type 2 pneumocytes and Clara cells of the small airways.

Studies on cell cultures and in vivo animal studies have shown that ambroxol stimulates the formation and secretion of a substance (surfactant) active on the surface of the alveoli and bronchi of the embryo and adult.

An antioxidant effect of ambroxol was also proven in preclinical studies. Ambroxol when used together with antibiotics (amoxicillin, cefuroxime, erythromycin and doxycycline) increases their concentration in sputum and bronchial secretion.

Pharmacokinetics

Ambroxol is almost completely absorbed from the gastrointestinal tract when taken orally. Maximum concentration is reached 1 to 3 hours after oral administration. Due to presystemic metabolism absolute bioavailability of ambroxol after oral administration is reduced by approximately ⅓. The resulting metabolites (such as dibromoanthranilic acid, glucuronides) are eliminated in the kidneys. Binding to plasma proteins is about 85% (80-90%). The plasma elimination half-life is 7 to 12 hours. The total half-life of ambroxol and its metabolites is approximately 22 hours.

Extracted mainly by the kidneys as metabolites – 90%, less than 10% is excreted unchanged.

Bearing in mind the high plasma protein binding, large volume of distribution and slow redistribution from tissues into blood, there is no significant excretion of ambroxol with dialysis or forced diuresis.

In patients with severe liver disease ambroxol clearance is reduced by 20-40 %. In patients with severe renal impairment the half-life of ambroxol metabolites is prolonged.

Ambroxol penetrates into the cerebrospinal fluid and through the placental barrier, and is excreted in breast milk.

Ambroxol does not occur in patients with severe liver disease.

Indications

Acute and chronic diseases of the respiratory tract, accompanied by impaired formation and discharge of sputum.

Pharmacological effect

Pharmacotherapeutic group: mucolytic expectorant.

ATX code: R05CB06

Pharmacological action

Pharmacodynamics:

Ambroxol is a benzylamine metabolite of bromhexine. It differs from bromhexine in the absence of a methyl group and the presence of a hydroxyl group in the para-trans position of the cyclohexyl ring. It has secretomotor, secretolytic and expectorant effects.

After oral administration, the effect occurs within 30 minutes and lasts for 6-12 hours (depending on the dose taken).

Preclinical studies have shown that ambroxol stimulates the serous cells of the glands of the bronchial mucosa. By activating ciliated epithelial cells and reducing sputum viscosity, it improves mucociliary transport.

Ambroxol activates the formation of surfactant, having a direct effect on type 2 alveolar pneumocytes and Clara cells of the small airways.

Studies on cell cultures and in vivo studies on animals have shown that ambroxol stimulates the formation and secretion of a substance (surfactant) active on the surface of the alveoli and bronchi of the embryo and adult.

Also, preclinical studies have proven the antioxidant effect of ambroxol. Ambroxol, when used together with antibiotics (amoxicillin, cefuroxime, erythromycin and doxycycline), increases their concentration in sputum and bronchial secretions.

Pharmacokinetics

When taken orally, ambroxol is almost completely absorbed from the gastrointestinal tract. The maximum concentration is achieved 1-3 hours after oral administration. Due to first-pass metabolism, the absolute bioavailability of ambroxol after oral administration is reduced by approximately ⅓. The resulting metabolites (such as dibromoanthranilic acid, glucuronides) are eliminated in the kidneys. Plasma protein binding is about 85% (80-90%). The plasma half-life ranges from 7 to 12 hours. The total half-life of ambroxol and its metabolites is approximately 22 hours.

It is excreted mainly by the kidneys in the form of metabolites – 90%, less than 10% is excreted unchanged.

Given the high binding to plasma proteins, large volume of distribution and slow redistribution from tissues to blood, significant elimination of ambroxol does not occur during dialysis or forced diuresis.

In patients with severe liver disease, the clearance of ambroxol is reduced by 20-40%. In patients with severe renal impairment, the half-life of ambroxol metabolites increases.

Ambroxol penetrates into the cerebrospinal fluid and through the placental barrier, and is also excreted into breast milk.

Special instructions

It should not be combined with antitussive drugs that impede the removal of sputum.
Severe skin reactions, such as Stevens-Johnson syndrome and Lyell’s syndrome, have been observed extremely rarely when using Ambrobene. If there is a change in the skin or mucous membranes, you must immediately consult a doctor and stop taking the drug.
The effect on the ability to drive vehicles and control machines and mechanisms is still unknown.

Active ingredient

Ambroxol

Composition

1 tablet contains: active ingredient ambroxol hydrochloride 30.00 mg; excipients: lactose monohydrate 169.46 mg, corn starch 36.33 mg, magnesium stearate 2.41 mg, colloidal anhydrous silicon dioxide 1.80 mg.

Pregnancy

Pregnancy:

There is insufficient data regarding the use of ambroxol during pregnancy. In particular, this applies to the first 28 weeks of pregnancy. Animal studies have not revealed a teratogenic effect.

The use of Ambrobene during pregnancy (II-III trimester) is possible only as prescribed by a doctor, after a careful assessment of the risk/benefit ratio.

Breastfeeding period:

Animal studies have shown that ambroxol passes into breast milk. Due to insufficient study of the use of the drug in women during breastfeeding, the use of Ambrobene is possible only as prescribed by a doctor, after a careful assessment of the risk/benefit ratio.

Contraindications

– hypersensitivity to ambroxol or one of the excipients;

– use in children under 6 years of age;

– pregnancy (first trimester);

– lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

With caution:

Impaired bronchial motor function and increased sputum production (with fixed cilia syndrome), peptic ulcer of the stomach and duodenum during exacerbation, pregnancy (II-III trimester), lactation period.

Patients with impaired renal function or severe liver disease should take Ambrobene with extreme caution, observing long intervals between doses or taking the drug in a lower dose.

Side Effects

General violations:

Rarely (from ≥ 0.1% to < 1%): allergic reactions (urticaria, skin rash, angioedema of the face, shortness of breath, itching), fever, weakness, headache.

Very rare (<0.01%): anaphylactic reactions, including anaphylactic shock.

From the gastrointestinal tract:

Rarely (from ≥ 0.1% to < 1%): nausea, abdominal pain, vomiting, diarrhea, constipation.

Others:

Rarely (from ≥ 0.1% to < 1%): dryness of the oral mucosa and respiratory tract, exanthema, rhinorrhea, dysuria.

Interaction

With the simultaneous use of ambroxol and antitussives, stagnation of secretions may occur due to suppression of the cough reflex. Therefore, such combinations should be selected with caution.
When ambroxol is taken together with the antibiotics amoxicillin, cefuroxime, erythromycin and doxycycline, the concentration of the latter in sputum and bronchial secretions increases.

Overdose

Symptoms:

There were no signs of intoxication with an overdose of ambroxol. There are reports of nervous agitation and diarrhea.

Ambroxol is well tolerated when taken orally at doses up to 25 mg/kg/day.

In case of severe overdose, increased salivation, nausea, vomiting, and decreased blood pressure are possible.

Treatment:

Intensive therapy methods, such as inducing vomiting and gastric lavage, should be used only in cases of severe overdose, in the first 1-2 hours after taking the drug. Symptomatic treatment is indicated.

Storage conditions

Store at a temperature not exceeding 25 0C
Keep out of the reach of children!

Shelf life

5 years

Manufacturer

Merkle GmbH, Germany